Home › Stomach Cancer › New York › New York City
Stomach Cancer clinical trials in New York City, NY
31 studies for Stomach Cancer are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- Memorial Sloan Kettering Hospital, New York
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
RecruitingPhase 2/3
- Memorial Sloan Kettering Cancer Center, New York
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
RecruitingPhase 3
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
RecruitingPhase 2/3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Rockefeller Outpatient Pavilion (53rd Street), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
RecruitingPhase 2
- Research Site, New York
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecruitingPhase 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
RecruitingPhase 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RecruitingPhase 1
- Icahn School of Medicine at Mount Sinai, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Hospital, New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RecruitingPhase 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center - MAIN, New York
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RecruitingPhase 1
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
RecruitingPhase 2
- Research Site, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecruitingPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
RecruitingObservational studyHealthy volunteers welcome
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
Avutometinib and Defactinib in Diffuse Gastric Cancer
RecruitingPhase 2
- Columbia University Irving Medical Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
Comprehensive Outcomes for After Cancer Health
RecruitingHealthy volunteers welcome
- Memorial Sloan Kettering Cancer Center, New York
About Stomach Cancer
Did you know risk factors for stomach (gastric) cancer include a diet high in salty or smoked food or having an H. pylori infection? Learn more here.
More about Stomach Cancer on MedlinePlus
Stomach Cancer trials in other cities
- Houston, TX42 studies
- Boston, MA32 studies
- Nashville, TN28 studies
- Baldwin Park, CA22 studies
- Los Angeles, CA22 studies
- Arlington, VA20 studies
- Dallas, TX19 studies
- San Antonio, TX19 studies
- Grand Rapids, MI18 studies
- St. Louis, MO18 studies
- Washington, DC16 studies
- Chicago, IL16 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.